Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3936223rdf:typepubmed:Citationlld:pubmed
pubmed-article:3936223lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0009325lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0015127lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0033532lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0033541lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0040060lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0370220lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0332621lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C1948023lld:lifeskim
pubmed-article:3936223lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:3936223pubmed:issue6lld:pubmed
pubmed-article:3936223pubmed:dateCreated1986-1-29lld:pubmed
pubmed-article:3936223pubmed:abstractTextProstanoid synthesis and release during collagen-induced aggregation of human platelet rich plasma (PRP) was studied using a novel gas chromatography/mass spectrometry assay technique. Aggregation was associated with the production of mainly thromboxane A2 (TXA2), measured as TXB2, and smaller amounts of the prostaglandins (PGs) D2, E2 and F2 alpha. UK 37,248 inhibited TXB2 formation by greater than 95% and increased the production of PGD2, PGE2 and PGF2 alpha twenty-fold. The relative amounts of these three prostanoids were not changed by UK 37,248. Even though high concentrations of PGD2 were formed, aggregation was not inhibited. In contrast, flurbiprofen inhibited aggregation, demonstrating that platelet aggregation produced by this concentration of collagen is cyclooxygenase dependent. These results support the proposal that the prostaglandin endoperoxides can induce aggregation alone, irrespective of the amount of PGD2 that is produced.lld:pubmed
pubmed-article:3936223pubmed:languageenglld:pubmed
pubmed-article:3936223pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:citationSubsetIMlld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3936223pubmed:statusMEDLINElld:pubmed
pubmed-article:3936223pubmed:monthSeplld:pubmed
pubmed-article:3936223pubmed:issn0049-3848lld:pubmed
pubmed-article:3936223pubmed:authorpubmed-author:LewisP JPJlld:pubmed
pubmed-article:3936223pubmed:authorpubmed-author:BlairI AIAlld:pubmed
pubmed-article:3936223pubmed:authorpubmed-author:WaddellK AKAlld:pubmed
pubmed-article:3936223pubmed:authorpubmed-author:OrchardM AMAlld:pubmed
pubmed-article:3936223pubmed:issnTypePrintlld:pubmed
pubmed-article:3936223pubmed:day15lld:pubmed
pubmed-article:3936223pubmed:volume39lld:pubmed
pubmed-article:3936223pubmed:ownerNLMlld:pubmed
pubmed-article:3936223pubmed:authorsCompleteYlld:pubmed
pubmed-article:3936223pubmed:pagination701-10lld:pubmed
pubmed-article:3936223pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:meshHeadingpubmed-meshheading:3936223-...lld:pubmed
pubmed-article:3936223pubmed:year1985lld:pubmed
pubmed-article:3936223pubmed:articleTitleThromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma.lld:pubmed
pubmed-article:3936223pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3936223pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:3936223pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3936223lld:pubmed